Notably, even though anti-IL6 treatment did not influence tumour volume (Figure 6A), the percentage of Tregs (Figure 6B) and Gr-MDSCs (Figure 6C) decreased by a factor of two, and the CD8/Tregs ratio increased in anti-IL-6-treated tumours, compared to control tumours (Figure 6D). The gene discussed is CD8A; the disease is neoplasm.